戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ain in which dimerization was regulated by a bivalent ligand.
2 s with five flexible arms each ending with a bivalent ligand.
3 nding properties of nanometer-scale flexible bivalent ligands.
4 tween mu and delta opioid receptors by using bivalent ligands.
5 roviding evidence of the discrete effects of bivalent ligands.
6 HIV-1(BaL) activity over previously reported bivalent ligands.
7 odels of hMCRs in complex with the developed bivalent ligands.
8 possibility, we have synthesized a series of bivalent ligands 1-5 that contain both mu agonist and CB
9                       However, the analogous bivalent ligand 15 comprised of two (-)-trans-piperidine
10                          In this series, the bivalent ligand 16, comprised of two (+)-trans-piperidin
11          In the dual receptor-bearing cells, bivalent ligands 3a-c capable of simultaneously binding
12      A functional switch is observed for the bivalent ligands 3b,c inhibiting cAMP formation in cells
13                                              Bivalent ligand 4 with spacer too short to occupy both r
14 is selectivity has led to the synthesis of a bivalent ligand (5) whose linker constrains the N17' bas
15                            Finally, selected bivalent ligands (5d and 7b) were able to attenuate the
16 odel, which mimicked the interaction between bivalent ligands and their target molecules, to investig
17 ties compared to their parent compounds, the bivalent ligand approach led to significantly higher aff
18                                          The bivalent ligands are H(2)R partial or full agonists, up
19                                The assembled bivalent ligands are significantly more potent inhibitor
20 sis for our continuing investigation of such bivalent ligands as probes of the opioid receptor oligom
21                      The affinities of these bivalent ligands at CB1 and CB2 receptors were determine
22                         Our investigation of bivalent ligands at mu, delta, and kappa opioid receptor
23 e unexpected observation that intermolecular bivalent ligand binding is enhanced for bivalent ligands
24  blocking required to prevent intermolecular bivalent ligand binding.
25                                              Bivalent ligands bridged in the 2-position were also syn
26 ide in complex with human FcRn shows how the bivalent ligand can bridge two FcRn molecules, which may
27          Receptor tethering with appropriate bivalent ligands can down-regulate signaling by moving a
28 to create nearly instantaneous high-affinity bivalent ligands capable of sequestering cellular target
29                                 A library of bivalent ligands composed of two identical CB1 antagonis
30                   In addition to binding the bivalent ligands, concanavalin A discriminated between C
31                               We report here bivalent ligands consisting of two identical oxytocin-mi
32 ive BRET signal, on exposure of the cells to bivalent ligands containing mu-opioid agonist and CCK2 r
33                                 All of these bivalent ligands effectively bind and cross-link anti-DN
34     Enforced dimerization of FKBP-BAX by the bivalent ligand FK1012 resulted in its translocation to
35 l synthesis and biological investigations of bivalent ligands for dopamine D2 receptor/neurotensin NT
36 exible linkers, we constructed aptamer-based bivalent ligands for human alpha-thrombin.
37 sed rigid oligoproline backbones to generate bivalent ligands for the gastrin-releasing peptide recep
38 ptide-linked, spatially segregated mono- and bivalent ligands for the legume lectin concanavalin A.
39 ity of ErbB receptors to dimerize to signal, bivalent ligands, formed by the synthetic linkage of two
40                 In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies r
41                           The development of bivalent ligands has attracted interest as a way to pote
42  attempt to enhance this effect, we prepared bivalent ligands incorporating CCK(2) receptor antagonis
43 d mGlu(2) ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-H
44                       We also show that, for bivalent ligands, inhibitory capacity is correlated with
45 he first time that an appropriately designed bivalent ligand is capable of inducing association of G-
46 delta- and kappa-opioid receptor phenotypes, bivalent ligands (KDAN series) containing delta-antagoni
47 valuated (intrathecally in mice) a series of bivalent ligands (KDN series) containing kappa and delta
48 nditions defining the total concentration of bivalent ligand [L2]0, the total concentration of protei
49 lved in such cross-talk, we have synthesized bivalent ligands (MCC series) that contain mu opioid ago
50 e by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-antagonist (MDAN) ser
51 nce to examine the dissociation of a soluble bivalent ligand, N, N'-bis[[epsilon-[(2,4-dinitrophenyl)
52  laboratory established that the symmetrical bivalent ligand, N,N'-bis-[[epsilon-(2,4-dinitrophenyl)a
53 ne units through a rigid pyrrole spacer, the bivalent ligand norbinaltorphimine was formed.
54 ments demonstrate that FGF23-WT can act as a bivalent ligand of KLA in the cell membrane.
55                                              Bivalent ligands of G protein-coupled receptors have bee
56 t a new chemical genetic method for creating bivalent ligands of protein kinases.
57 ential formation of intra-IgE cross-links by bivalent ligands of sufficient length, (ii) self-associa
58 present in a complex of two proteins and one bivalent ligand (P x L2 x P) is maximized at [L2]0 = Kd/
59 comparison of the experimental data with the bivalent ligand properties predicted by a wormlike chain
60                      The development of this bivalent ligand provides a tool for further probing the
61 ular bivalent ligand binding is enhanced for bivalent ligands relative to monovalent ligands allowed
62                The newly discovered oxytocin bivalent ligands represent a powerful tool for targeting
63 , this is the first report of a melanocortin bivalent ligand's in vivo physiological effects.
64              Moreover, the newly synthesized bivalent ligands show a strong, predominantly NTS1R-medi
65                                          The bivalent ligands show binding affinity in the picomolar
66 affinity compared to O-methyl glycoside, two bivalent ligands show significant enhancements in affini
67                      Unexpectedly, different bivalent ligands showed preferences for particular melan
68  synthesis, and biological investigations of bivalent ligands targeting putative mu opioid receptor C
69 ons involving Fc epsilon RI, Lyn, Syk, and a bivalent ligand that aggregates Fc(epsilon)RI.
70                                   KDN21 is a bivalent ligand that contains delta and kappa opioid ant
71  with a spacer length of 43-atoms, as a true bivalent ligand that simultaneously binds to the two dif
72 keeping the site available for high-affinity bivalent ligands that can bind multiple sites in Nck.
73 d by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGlu
74 valent complexes with a stoichiometry of one bivalent ligand to one dimer.
75 ffold on the binding of these monovalent and bivalent ligands to anti-DNP IgE in solution.
76          The stoichiometry of binding of the bivalent ligands to both di- and tetrameric lectin was t
77 ent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-TM
78 study focused on the design and synthesis of bivalent ligands to target melanocortin receptor homodim
79 84, the prototype of our previously reported bivalent ligand TTR 'superstabiliser' family, is notably
80                         We present unmatched bivalent ligands (UmBLs) to study the asymmetric functio
81                                          The bivalent ligand VZMC013 possessed nanomolar level bindin
82                       Novel piperidine-based bivalent ligands were prepared in enantiomerically pure
83  and the anticlotting activities of thrombin bivalent ligands were significantly improved compared to
84                    The 16 and 18 atom spacer bivalent ligands were the highlight compounds, displayin
85 ental analyses, that palmitoyl CoA acts as a bivalent ligand where the interaction of the DHHC enzyme
86 cope of the method, the assembly of a set of bivalent ligands, which integrate members of the epiderm
87          In contrast, mds84, our prototypic "bivalent" ligand, which is a more potent stabilizer of T
88 nked with a long flexible linker to create a bivalent ligand with significantly improved binding affi
89 of cell surface receptors by a collection of bivalent ligands with different affinities for the recep
90 a nanometer-scale flexible linker to produce bivalent ligands with improved binding affinity and spec
91               This dimer binds the series of bivalent ligands with low picomolar avidities (K(d)(avid
92                To verify the practicality of bivalent ligands with nanometer-scale flexible linkers,
93                                The resulting bivalent ligands with optimized spacer length and struct